Programme Day 3

• Revisiting the β-cell: The Key to the Type 2 Diabetes Puzzle
  Steven KahnUnited States Speaker Revisiting the β-cell: The Key to the Type 2 Diabetes Puzzle(TBC)

• Paraneoplastic Autoimmune Hypophysitis: A Novel Form Paraneoplastic Endocrine Syndrome
  Yutaka TakahashiJapan Speaker Paraneoplastic Autoimmune Hypophysitis: A Novel Form Paraneoplastic Endocrine SyndromeHypophysitis: Difficult Cases

• The Danger of Obesity in South East Asia
  Vivien LimSingapore Speaker The Danger of Obesity in South East Asia
• Changing Paradigms of Obesity Management in Asia-Oceania
  Nitin KapoorIndia Speaker Changing Paradigms of Obesity Management in Asia-Oceania
• Obesity - MASLD Perspectives in Asia-Oceania
  Abbas RazaPakistan Speaker Changing Paradigms of Obesity Management in Asia-Oceania

• Pathophysiological Mechanisms Underlying Diabetic Neuropathy
  Chih-Cheng ChenTaiwan Speaker Pathophysiological Mechanisms Underlying Diabetic Neuropathy
• Clinical Presentation and Diagnostic Evaluation of Diabetic Neuropathy
  Chi-Chao ChaoTaiwan Speaker Clinical Presentation and Diagnostic Evaluation of Diabetic Neuropathy
• Evidence-Based Management of Diabetic Neuropathy: Pharmacologic and Non-Pharmacologic Approaches
  Yen-Feng Wang Taiwan Speaker Evidence-Based Management of Diabetic Neuropathy: Pharmacologic and Non-Pharmacologic Approaches

• Advances in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Multikinase Inhibitors and Beyond – An Asian Perspective
  Won Gu KimKorea (Republic of) Speaker Advances in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Multikinase Inhibitors and Beyond – An Asian Perspective
• The Genetic Landscape of Thyroid Cancer
  Young Joo ParkKorea (Republic of) Speaker Translating the Genetic Landscape of Thyroid Cancer to Precision Diagnosis and TherapyThyroid cancer is characterized by a relatively low mutational burden compared with other solid tumors, with recurrent alterations mainly involving BRAF, RAS, and various fusion genes. Several novel driver candidates have also been identified through next-generation sequencing studies. The frequency and pattern of these genomic alterations differ across thyroid cancer subtypes and are often associated with distinct histopathological phenotypes, providing valuable clues for differential diagnosis. Moreover, molecular subtypes defined by driver mutations are closely linked to tumor biology and clinical behavior, allowing more accurate prediction of disease aggressiveness and prognosis. Most differentiated thyroid cancers (DTCs) harbor a single dominant driver alteration; however, acquisition of additional mutations such as TERT promoter, tumor suppressor genes, or PI3K–AKT pathway alterations may lead to dedifferentiation and progression to aggressive or metastatic disease. Advances in our understanding of these genetic alterations have refined the pathological classification of thyroid cancer and enabled improved prognostication, treatment selection, and follow-up strategies. Importantly, the identification of actionable genetic alterations—including RET and NTRK fusions, as well as BRAF mutations—has revolutionized therapeutic approaches. Targeted agents such as selpercatinib, pralsetinib, larotrectinib, and entrectinib demonstrate substantial clinical efficacy with fewer adverse events than multikinase inhibitors, while dabrafenib plus trametinib has shown marked benefit in anaplastic thyroid cancer. With multiple targetable mutations being uncovered, incorporating comprehensive genomic testing into the diagnostic workflow is essential to guide precision therapy for patients with thyroid cancer.
• Redifferentiation Strategies in Refractory Thyroid Cancer: First Insights from Taiwan
  He-Jiun JiangTaiwan Speaker Redifferentiation Strategies in Refractory Thyroid Cancer: First Insights from Taiwan

• Stereotactic Radiosurgery for Cushing Disease
  Cheng-Chia LeeTaiwan Speaker Stereotactic Radiosurgery for Cushing Disease
• Treatment of Recurrence/Persistence of Cushing Disease: Role of Medical Therapy
  Seung Shin ParkKorea (Republic of) Speaker Treatment of Recurrence/Persistence of Cushing Disease: Role of Medical Therapy
• Beyond Cushing’s Syndrome: The Future of Research in Cortisol Dysregulation
  Masaaki YamamotoUnited States Speaker Beyond Cushing’s Syndrome: The Future of Research in Cortisol Dysregulation

• Update in Management of Pheochromocytoma and Paraganglioma
  Akiyo TanabeJapan Speaker Update in Management of Pheochromocytoma and Paraganglioma
• What's New in the Adrenal Medulla?
  Roderick Clifton-BlighAustralia Speaker What's New in the Adrenal Medulla?
• Genetics of Paragangliomas (Pheochromocytomas)
  Wan-Chen WuTaiwan Speaker Genetics of Paragangliomas (Pheochromocytomas)

• Diabetes and Heart Failure: A Dual Epidemic
  Kuo-Meng LiaoTaiwan Speaker Diabetes and Heart Failure: A Dual Epidemic
• Metabolic Dysfunction and Brain Health: Diabetes as a Risk Factor for Dementia
  Jong-Ling FuhTaiwan Speaker Metabolic Dysfunction and Brain Health: Diabetes as a Risk Factor for Dementia
• Sleep Apnea in Diabetes: A Silent Aggravator
  Li-Pang ChuangTaiwan Speaker Sleep Apnea in Diabetes: A Silent AggravatorObstructive sleep apnea (OSA) is a highly prevalent clinical disease affecting more than 10% of the adult population. It is characterized by repetitive episodes of partial or total upper airway obstruction during sleep, resulting in subsequent sleep fragmentation and intermittent hypoxia. Accumulating studies reveal that OSA is an independent risk factor for consequent cardiovascular morbidities, such as myocardial infarction, heart failure, nocturnal dysrhythmias and pulmonary hypertension. Currently, OSA can be treated by means of positive airway pressure therapy, pharmacological therapy and surgical intervention. OSA is a silent aggravator of diabetes because it worsens glucose metabolism and insulin resistance through mechanisms like intermittent hypoxia, sleep fragmentation, and sympathetic nervous system activation. This creates a bidirectional relationship where OSA increases the risk and severity of diabetes, and diabetes can worsen OSA. Treating OSA may improve glycemic control, and screening for it is crucial, especially in individuals with type 2 diabetes, particularly those who are obese.

• (TBC)
  Hung-Yuan Li Speaker

• (TBC)
  Steven KahnUnited States Speaker Revisiting the β-cell: The Key to the Type 2 Diabetes Puzzle(TBC)

• Challenging Cases in Endocrinology
  Ronald MaHong Kong, China Speaker Precision Medicine in Diabetes: Perspectives from AsiaChallenging Cases in Endocrinology

• Hypophysitis: Difficult Cases
  Yutaka TakahashiJapan Speaker Paraneoplastic Autoimmune Hypophysitis: A Novel Form Paraneoplastic Endocrine SyndromeHypophysitis: Difficult Cases

• (TBC)
  Hirotaka ShibataJapan Speaker 2026 Update in Primary Aldosteronism

• Insulin as Lifeline: Optimizing Regimens in Type 1 Diabetes
  Yi-Ching TungTaiwan Speaker Insulin as Lifeline: Optimizing Regimens in Type 1 Diabetes
• When, What, and How: Practical Approaches to Insulin Use in Type 2 Diabetes
  Ju-Ying JiangTaiwan Speaker When, What, and How: Practical Approaches to Insulin Use in Type 2 Diabetes
• The New Era of Insulin Therapy: Ultra-Long Acting, Smart Delivery, and Beyond
  Jia-Hong Lin Speaker The New Era of Insulin Therapy: Ultra-Long Acting, Smart Delivery, and Beyond

• Management of Transgender Individuals: Psychiatrist Perspectives
  Wayne Wing Ki TangHong Kong, China Speaker Management of Transgender Individuals: Psychiatrist Perspectives
• Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults
  Brendan NolanAustralia Speaker Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults
• Gender-Affirming Hormone Therapy in Taiwan
  Pei-Lung ChenTaiwan Speaker Gender-Affirming Hormone Therapy in Taiwan

• Acromegaly and Cardiovascular Disease: The Research in Taipei Veterans General Hospital
  Harn-Shen ChenTaiwan Speaker Acromegaly and Cardiovascular Disease: The Research in Taipei Veterans General Hospital
• Medication Management for Acromegaly
  Cheol Ryong KuKorea (Republic of) Speaker Medication Management for Acromegaly
• Acromegaly: GH Response Pattern to Oral Glucose Load and Personalized Medicine
  Michio OtsukiJapan Speaker Acromegaly: GH Response Pattern to Oral Glucose Load and Personalized Medicine

• AI and Clinical Decision Support System (CDSS) for Type 1 Diabetes
  Luqman IbrahimMalaysia Speaker AI and Clinical Decision Support System (CDSS) for Type 1 Diabetes
• AI applications and insulin management
  Iris Isip-TanPhilippines Speaker AI applications and insulin management
• Precision Diabetes Clustering for Young-Onset Diabetes (in Indonesia Populations)
  Dicky L. TahaparyIndonesia Speaker Precision Diabetes Clustering for Young-Onset Diabetes (in Indonesia Populations)

• (TBC)
  Hsiu-Hsi ChenTaiwan Speaker
• AI-Assisted Discovery of Omic Signature in Diabetic Kidney Disease
  I-Wen WuTaiwan Speaker AI-Assisted Discovery of Omic Signature in Diabetic Kidney Disease
• How to Use AI in Clinical Study?
  Dee Pei Speaker How to Use AI in Clinical Study?